600079 ST人福
已收盘 07-24 15:00:00
资讯
新帖
简况
每周股票复盘:ST人福(600079)拟每股派现0.48元
证券之星 · 01:47
每周股票复盘:ST人福(600079)拟每股派现0.48元
ST人福(600079)披露2025年年度权益分派实施公告,7月24日股价下跌1.66%
证券之星 · 07-24 22:15
ST人福(600079)披露2025年年度权益分派实施公告,7月24日股价下跌1.66%
ST人福:公司积极关注并探索新技术在药物研发过程中的应用
证券之星 · 07-24 16:39
ST人福:公司积极关注并探索新技术在药物研发过程中的应用
ST人福:调整定增定价基准日更好保护中小股东
证券之星 · 07-24 16:39
ST人福:调整定增定价基准日更好保护中小股东
ST人福:盐酸他喷他多口服溶液用于缓解中度至重度急性疼痛
证券之星 · 07-24 16:33
ST人福:盐酸他喷他多口服溶液用于缓解中度至重度急性疼痛
ST人福(600079.SH)子公司酒石酸长春瑞滨软胶囊获得药品注册证书
智通财经 · 07-24 16:00
ST人福(600079.SH)子公司酒石酸长春瑞滨软胶囊获得药品注册证书
ST人福(600079)披露尼达尼布软胶囊获得美国FDA批准文号,7月10日股价上涨0.41%
证券之星 · 07-10
ST人福(600079)披露尼达尼布软胶囊获得美国FDA批准文号,7月10日股价上涨0.41%
ST人福(600079.SH):HW211026软膏进入II期临床试验研究
智通财经 · 07-09
ST人福(600079.SH):HW211026软膏进入II期临床试验研究
每周股票复盘:ST人福(600079)将参加2026年投资者集体接待日活动
证券之星 · 07-05
每周股票复盘:ST人福(600079)将参加2026年投资者集体接待日活动
ST人福获得发明专利授权:“非奈利酮的药物组合物及其制备方法和用途”
证券之星 · 07-04
ST人福获得发明专利授权:“非奈利酮的药物组合物及其制备方法和用途”
ST人福(600079)披露将参加湖北辖区上市公司2026年投资者集体接待日活动暨2025年度业绩说明会,6月30日股价下跌2.14%
证券之星 · 06-30
ST人福(600079)披露将参加湖北辖区上市公司2026年投资者集体接待日活动暨2025年度业绩说明会,6月30日股价下跌2.14%
ST人福(600079.SH)子公司注射用HWS113获得药物临床试验批准通知书
智通财经 · 06-25
ST人福(600079.SH)子公司注射用HWS113获得药物临床试验批准通知书
ST人福:二级市场波动受多重因素影响
证券之星 · 06-24
ST人福:二级市场波动受多重因素影响
ST人福:公司拟通过本次发行向控股股东募集资金用于研发创新、产能升级和数智化建设
证券之星 · 06-24
ST人福:公司拟通过本次发行向控股股东募集资金用于研发创新、产能升级和数智化建设
ST人福:调整定增定价基准日为发行期首日
证券之星 · 06-24
ST人福:调整定增定价基准日为发行期首日
ST人福:公司将在股东会审议通过之日起2个月内完成本次分红实施工作
证券之星 · 06-24
ST人福:公司将在股东会审议通过之日起2个月内完成本次分红实施工作
ST人福:子公司葛店人福已聘请第三方专业机构
证券之星 · 06-24
ST人福:子公司葛店人福已聘请第三方专业机构
ST人福:截至2026年3月31日公司普通股股东总数为80,842户
证券之星 · 06-24
ST人福:截至2026年3月31日公司普通股股东总数为80,842户
ST人福:生产销售化药仿制药
证券之星 · 06-24
ST人福:生产销售化药仿制药
ST人福:公司目前无相关计划
证券之星 · 06-24
ST人福:公司目前无相关计划
暂无数据
公司概况
公司名称:
人福医药集团股份公司
所属行业:
医药制造业
上市日期:
1997-06-06
主营业务:
人福医药集团股份公司的主营业务是以医药工业为主、医药商业为辅。公司的主要产品是枸橼酸舒芬太尼注射液、注射用盐酸瑞芬太尼、盐酸氢吗啡酮注射液、盐酸纳布啡注射液、盐酸阿芬太尼注射液、注射用苯磺酸瑞马唑仑、米非司酮制剂、祖卡木颗粒、复方木尼孜其颗粒、注射用尿激酶、硫酸新霉素原料药、黄体酮原料药。经过30多年的发展,公司已成长为湖北省医药工业龙头企业、中国医药工业20强、国家企业技术中心、国家技术创新示范企业、中国医药企业制剂国际化先导企业。
发行价格:
5.22
{"stockData":{"symbol":"600079","market":"SH","secType":"STK","nameCN":"ST人福","latestPrice":17.19,"timestamp":1784876401000,"preClose":17.48,"halted":0,"volume":10462151,"delay":0,"changeRate":-0.0166,"floatShares":1543000000,"shares":1632000000,"eps":1.166,"marketStatus":"已收盘","change":-0.29,"latestTime":"07-24 15:00:00","open":17.4,"high":17.48,"low":17.19,"amount":181000000,"amplitude":0.0166,"askPrice":17.2,"askSize":448,"bidPrice":17.19,"bidSize":581,"shortable":0,"etf":0,"ttmEps":1.166,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785115800000},"marketStatusCode":5,"adr":0,"adjPreClose":17.48,"symbolType":"stock","openAndCloseTimeList":[[1784856600000,1784863800000],[1784869200000,1784876400000]],"highLimit":18.35,"lowLimit":16.61,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":1632225965,"isCdr":false,"pbRate":1.45,"roa":"--","peRate":14.74271,"roe":"3.07%","epsLYR":1.14,"committee":0.394357,"marketValue":28058000000,"turnoverRate":0.0068,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-07-27。","floatMarketCap":26527000000},"requestUrl":"/m/hq/s/600079/tweets","defaultTab":"tweets","newsList":[{"id":"2654284052","title":"每周股票复盘:ST人福(600079)拟每股派现0.48元","url":"https://stock-news.laohu8.com/highlight/detail?id=2654284052","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654284052?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:47","pubTimestamp":1785001631,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘,ST人福报收于17.19元,较上周的17.45元下跌1.49%。本周,ST人福7月20日盘中最高价报17.81元。本周关注点公司公告汇总:ST人福拟每股派发现金红利0.48元(含税)。公司公告汇总人福医药集团股份公司2025年年度权益分派实施公告:每股派发现金红利0.48元(含税),股权登记日为2026年7月31日,除权(息)日为2026年8月3日,现金红利发放日为2026年8月3日。本次利润分配以公司总股本1,632,225,965股为基数,共派发现金红利783,468,463.20元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0096","BK0070","BK0028","BK0012","600079","BK0185","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653038182","title":"ST人福(600079)披露2025年年度权益分派实施公告,7月24日股价下跌1.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653038182","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653038182?lang=zh_cn&edition=full","pubTime":"2026-07-24 22:15","pubTimestamp":1784902524,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘,ST人福报收于17.19元,较前一交易日下跌1.66%,最新总市值为280.58亿元。该股当日开盘17.4元,最高17.48元,最低17.19元,成交额达1.81亿元,换手率为0.68%。公司近日披露《2025年年度权益分派实施公告》:每股派发现金红利0.48元(含税),股权登记日为2026年7月31日,除权(息)日为2026年8月3日,现金红利发放日为2026年8月3日。本次利润分配以公司总股本1,632,225,965股为基数,共派发现金红利783,468,463.20元。部分股东红利由公司自行发放。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400041901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0070","600079","BK0188","BK0096","BK0239","BK0185","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653003587","title":"ST人福:公司积极关注并探索新技术在药物研发过程中的应用","url":"https://stock-news.laohu8.com/highlight/detail?id=2653003587","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653003587?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:39","pubTimestamp":1784882360,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福(600079)07月24日在投资者关系平台上答复投资者关心的问题。投资者提问:公司有Ai制药布局吗ST人福回复:尊敬的投资者,您好!公司积极关注并探索新技术在药物研发过程中的应用,相关布局及应用情况请查阅公司2025年年度报告“管理层讨论与分析”部分。感谢您对公司的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400028616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0012","600079","BK0070","BK0096","BK0185","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653700317","title":"ST人福:调整定增定价基准日更好保护中小股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2653700317","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653700317?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:39","pubTimestamp":1784882356,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福07月24日在投资者关系平台上答复投资者关心的问题。公司本次调整的是定增定价基准日,即将定价基准日调整为“发行期首日”,调整后的定价更加贴近市场公允价格,遵循了市场化原则,从机制上能更好地保护中小股东。公司始终秉持公平公正原则,切实维护广大投资者特别是中小股东的合法权益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400028615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0012","BK0028","600079","BK0185","BK0239","BK0070","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653707127","title":"ST人福:盐酸他喷他多口服溶液用于缓解中度至重度急性疼痛","url":"https://stock-news.laohu8.com/highlight/detail?id=2653707127","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653707127?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:33","pubTimestamp":1784881996,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福07月24日在投资者关系平台上答复投资者关心的问题。盐酸他喷他多口服溶液主要用于缓解体重超过16kg的2岁以上儿童和成人的中度至重度急性疼痛,目前尚未在国内上市,该产品能满足差异化临床需求,进一步丰富公司镇痛产品梯队。目前该项目尚处于临床试验阶段,未来销售具有不确定性,敬请注意投资风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400028444.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","BK0028","BK0188","BK0185","BK0096","BK0070","600079"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653702299","title":"ST人福(600079.SH)子公司酒石酸长春瑞滨软胶囊获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2653702299","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653702299?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:00","pubTimestamp":1784880020,"startTime":"0","endTime":"0","summary":"智通财经APP讯,ST人福 发布公告,公司全资子公司人福普克药业(武汉)有限公司近日收到国家药品监督管理局核准签发的酒石酸长春瑞滨软胶囊的《药品注册证书》。据悉,酒石酸长春瑞滨软胶囊被批准用于不可手术切除的局部晚期或转移性非小细胞肺癌,和转移性乳腺癌的单药或联合化疗。武汉普克于2024年10月向国家药品监督管理局提交了酒石酸长春瑞滨软胶囊的上市许可申请并获得受理,截至目前,该项目累计研发投入约为1200万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471876.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ST人福(600079.SH)子公司酒石酸长春瑞滨软胶囊获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0096","BK0188","BK0239","BK0070","BK0028","BK0185","BK0012","600079"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650351031","title":"ST人福(600079)披露尼达尼布软胶囊获得美国FDA批准文号,7月10日股价上涨0.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650351031","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650351031?lang=zh_cn&edition=full","pubTime":"2026-07-10 22:14","pubTimestamp":1783692862,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘,ST人福报收于17.33元,较前一交易日上涨0.41%,最新总市值为282.86亿元。近日,人福医药集团股份公司全资子公司人福普克药业(武汉)有限公司收到美国食品药品监督管理局关于尼达尼布软胶囊的批准文号,ANDA批件号为218472,规格为100 mg和150 mg,适用于治疗特发性肺纤维化和具有进行性表型的慢性纤维化性间质性肺疾病。根据IQVIA数据,2025年1-9月该药品在美国销售额约为28亿美元。此次获批将有助于公司拓展美国仿制药市场。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000044341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","600079","BK0239","BK0070","BK0188","BK0012","BK0185","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650447679","title":"ST人福(600079.SH):HW211026软膏进入II期临床试验研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2650447679","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650447679?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:58","pubTimestamp":1783583899,"startTime":"0","endTime":"0","summary":"智通财经APP讯,ST人福(600079.SH)发布公告,公司全资子公司湖北生物医药产业技术研究院有限公司(简称“研究院有限公司”)近日在国家药品监督管理局药物临床试验登记与信息公示平台公示了HW211026软膏II期临床试验登记信息。试验名称:一项评价HW211026软膏治疗光线性角化病的有效性和安全性的多中心、开放标签、给药方案探索II期临床研究;试验目的:评估HW211026软膏治疗光线性角化病的有效性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465229.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0185","BK0028","BK0012","BK0096","600079","BK0070","BK0239","BMED","IBBQ","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649694941","title":"每周股票复盘:ST人福(600079)将参加2026年投资者集体接待日活动","url":"https://stock-news.laohu8.com/highlight/detail?id=2649694941","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649694941?lang=zh_cn&edition=full","pubTime":"2026-07-05 02:22","pubTimestamp":1783189332,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘,ST人福报收于17.77元,较上周的16.37元上涨8.55%。本周,ST人福7月3日盘中最高价报17.77元。6月29日盘中最低价报16.25元。ST人福当前最新总市值290.05亿元,在化学制药板块市值排名14/149,在两市A股市值排名746/5203。本周关注点公司公告汇总:ST人福将参加2026年7月9日举办的投资者集体接待日活动暨2025年度业绩说明会。活动时间为2026年7月9日14:00-17:00,公司高管将就2025年度业绩、公司治理、发展战略、经营状况等与投资者进行交流。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500000637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0239","600079","BK0028","BK0012","BK0188","BK0070","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648660435","title":"ST人福获得发明专利授权:“非奈利酮的药物组合物及其制备方法和用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2648660435","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648660435?lang=zh_cn&edition=full","pubTime":"2026-07-04 03:45","pubTimestamp":1783107929,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示ST人福新获得一项发明专利授权,专利名为“非奈利酮的药物组合物及其制备方法和用途”,专利申请号为CN202411440120.3,授权日为2026年7月3日。本发明的药物组合物在多种介质中具有较好的溶出度,制成制剂后具有较好的均匀度、耐受性和粒径尺寸,与参比制剂体外释放效果一致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070400003634.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600079","BK0096","BK0239","BK0188","BK0012","BK0185","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647534581","title":"ST人福(600079)披露将参加湖北辖区上市公司2026年投资者集体接待日活动暨2025年度业绩说明会,6月30日股价下跌2.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647534581","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647534581?lang=zh_cn&edition=full","pubTime":"2026-06-30 17:50","pubTimestamp":1782813036,"startTime":"0","endTime":"0","summary":"截至2026年6月30日收盘,ST人福报收于16.44元,较前一交易日下跌2.14%,最新总市值为268.34亿元。该股当日开盘16.71元,最高16.78元,最低16.4元,成交额达1.91亿元,换手率为0.75%。近日,ST人福发布《关于参加湖北辖区上市公司2026年投资者集体接待日活动暨2025年度业绩说明会的公告》。投资者可通过“全景路演”网站、微信公众号“全景财经”或全景路演APP参与。公司高管将在活动中就2025年度业绩、公司治理、发展战略、经营状况等与投资者进行交流。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000033388.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0239","600079","BK0188","BK0012","BK0096","BK0028","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646873824","title":"ST人福(600079.SH)子公司注射用HWS113获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2646873824","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646873824?lang=zh_cn&edition=full","pubTime":"2026-06-25 16:25","pubTimestamp":1782375912,"startTime":"0","endTime":"0","summary":"智通财经APP讯,ST人福(600079.SH)发布公告,公司全资子公司湖北生物医药产业技术研究院有限公司近日收到国家药品监督管理局核准签发的注射用HWS113的《药物临床试验批准通知书》。据悉,注射用HWS113是一款治疗用生物制品1类新药,拟用于慢性瘙痒的治疗。慢性瘙痒定义为瘙痒持续超过6周,其严重影响患者的生活质量,导致睡眠障碍、影响社交与工作,引起焦虑或抑郁等负面心理问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458642.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","600079","BK0012","BK0070","BK0028","BK0185","BK0239","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645893090","title":"ST人福:二级市场波动受多重因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2645893090","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645893090?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:30","pubTimestamp":1782289834,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福(600079)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问:每天起床就扣钱,还有救吗,尊敬的邓总ST人福回复:尊敬的投资者,您好!二级市场波动受宏观经济、行业政策、市场情绪及公司基本面等多重因素影响,敬请理性看待。感谢您对公司的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400029788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0185","BK0096","BK0070","600079","BK0239","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645389301","title":"ST人福:公司拟通过本次发行向控股股东募集资金用于研发创新、产能升级和数智化建设","url":"https://stock-news.laohu8.com/highlight/detail?id=2645389301","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645389301?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:27","pubTimestamp":1782289632,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福(600079)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问:战投部卢硕说贵司不缺的就是招商有资金,股价低迷何不进行回购注销这样岂不是达到招商提高股份占比的想法ST人福回复:尊敬的投资者,您好!股份回购的实施主体为上市公司而非控股股东。公司拟通过本次发行向控股股东募集资金用于研发创新、产能升级和数智化建设,旨在夯实核心主业竞争力、优化资本结构。公司将深耕核心医药业务,通过持续夯实经营基本面维护股东长期利益,感谢您对公司的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400029672.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0012","600079","BK0070","BK0096","BK0185","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645893057","title":"ST人福:调整定增定价基准日为发行期首日","url":"https://stock-news.laohu8.com/highlight/detail?id=2645893057","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645893057?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:27","pubTimestamp":1782289631,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福06月24日在投资者关系平台上答复投资者关心的问题。公司已于2026年6月18日召开董事会审议通过了调整定增定价基准日为发行期首日,保障定价公允,切实维护中小投资者利益。子公司葛店人福已聘请第三方专业机构推进厂区整改,并持续与FDA保持沟通,将尽快完成鄂州厂区整改、解除警示。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400029670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","600079","BK0185","BK0239","BK0028","BK0070","BK0188","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645932928","title":"ST人福:公司将在股东会审议通过之日起2个月内完成本次分红实施工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2645932928","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645932928?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:24","pubTimestamp":1782289484,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福(600079)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司上周五己召开股东大会通过2025年利润分配提案,什么时候可以实施分红ST人福回复:尊敬的投资者,您好!公司2025年年度利润分配方案已于2026年6月5日经2025年年度股东会审议通过,公司将在股东会审议通过之日起2个月内完成本次分红实施工作。感谢您对公司的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400029468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0012","BK0185","BK0070","BK0239","600079","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645932678","title":"ST人福:子公司葛店人福已聘请第三方专业机构","url":"https://stock-news.laohu8.com/highlight/detail?id=2645932678","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645932678?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:24","pubTimestamp":1782289482,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福(600079)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问:想问下关于FDA对葛店人福的警告信情况,是否引入第三方专业顾问是否需要提交延期申请,违规问题整改情况ST人福回复:尊敬的投资者,您好!子公司葛店人福已聘请第三方专业机构,并持续与FDA保持沟通,将尽快完成鄂州厂区整改、解除警示。感谢您对公司的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400029460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0239","BK0096","BK0070","BK0028","600079","BK0012","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645893298","title":"ST人福:截至2026年3月31日公司普通股股东总数为80,842户","url":"https://stock-news.laohu8.com/highlight/detail?id=2645893298","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645893298?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:24","pubTimestamp":1782289482,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福(600079)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问:请问截止2026年5月31日,公司股东人数多少?ST人福回复:尊敬的投资者,您好!根据上市公司信息披露相关规定以及信息披露原则,公司会在定期报告中披露对应时点的股东户数及前十名股东情况,敬请查阅公司在上海证券交易所网站上刊登的定期报告。公司最近一次披露的股东户数是截至2026年3月31日的公司普通股股东总数,为80,842户。感谢您对公司的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400029463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0070","600079","BK0188","BK0096","BK0239","BK0185","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645893262","title":"ST人福:生产销售化药仿制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2645893262","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645893262?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:24","pubTimestamp":1782289481,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福(600079)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问:公司在非洲的子公司生产经营的产品是什么?产品销售受限制吗?业务发展预期趋势怎么样?经营的效益好不好?ST人福回复:尊敬的投资者,您好!公司已在非洲马里、埃塞俄比亚建成现代化制药工厂,生产销售的产品为化药仿制药,主要满足当地及周边区域民众基础用药需求。公司积极克服当地政局动荡、能源短缺等困难,践行企业责任,保持稳定发展。感谢您对公司的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400029459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","600079","BK0188","BK0239","BK0070","BK0185","BK0096","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645893674","title":"ST人福:公司目前无相关计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2645893674","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645893674?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:09","pubTimestamp":1782288568,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福(600079)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问:新疆维药有没单独IPO的计划ST人福回复:尊敬的投资者,您好!公司目前无相关计划。感谢您对公司的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400027625.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0185","BK0096","BK0070","600079","BK0239","BK0012"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1785067640809,"stockEarnings":[{"period":"1week","weight":-0.0149},{"period":"1month","weight":0.0094},{"period":"3month","weight":-0.0758},{"period":"6month","weight":-0.0576},{"period":"1year","weight":-0.2137},{"period":"ytd","weight":-0.0508}],"compareEarnings":[{"period":"1week","weight":0.0133},{"period":"1month","weight":-0.0722},{"period":"3month","weight":-0.0651},{"period":"6month","weight":-0.0778},{"period":"1year","weight":0.0578},{"period":"ytd","weight":-0.039}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"人福医药集团股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"80842人(较上一季度减少3.87%)","perCapita":"19088股","listingDate":"1997-06-06","address":"湖北省武汉市洪山区东湖高新区高新大道666号","registeredCapital":"163222万元","survey":" 人福医药集团股份公司的主营业务是以医药工业为主、医药商业为辅。公司的主要产品是枸橼酸舒芬太尼注射液、注射用盐酸瑞芬太尼、盐酸氢吗啡酮注射液、盐酸纳布啡注射液、盐酸阿芬太尼注射液、注射用苯磺酸瑞马唑仑、米非司酮制剂、祖卡木颗粒、复方木尼孜其颗粒、注射用尿激酶、硫酸新霉素原料药、黄体酮原料药。经过30多年的发展,公司已成长为湖北省医药工业龙头企业、中国医药工业20强、国家企业技术中心、国家技术创新示范企业、中国医药企业制剂国际化先导企业。","listedPrice":5.22},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ST人福(600079)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ST人福(600079)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ST人福,600079,ST人福股票,ST人福股票老虎,ST人福股票老虎国际,ST人福行情,ST人福股票行情,ST人福股价,ST人福股市,ST人福股票价格,ST人福股票交易,ST人福股票购买,ST人福股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ST人福(600079)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ST人福(600079)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}